📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
206 analysed today
FollowTelegram
206
Today
149,607
All-time analysed
42,901
Positive
6,659
Negative
91,372
Neutral
8,607
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
49 announcements match the current filters (relevance ≥ 5).
Religare Enterprises Allots 83.43 Lakh Equity Shares on Warrant Conversion; Raises Rs 147 Cr
Religare Enterprises Limited has allotted 83,43,263 equity shares following the conversion of warrants by five key investors, including Ashish Dhawan and JM Financial Credit Solutions. The company received Rs 147.05 crore, representing the final 75% payment of the total consideration of Rs 235 per share. This conversion increases the company's paid-up equity capital from Rs 332.89 crore to Rs 341.23 crore. The move strengthens the balance sheet and reflects continued commitment from high-profile warrant holders.
Key Highlights
Allotment of 83,43,263 equity shares of face value Rs 10 at a premium of Rs 225 per share.
Receipt of Rs 147,05,00,104.25 representing the remaining 75% consideration for the warrants.
Key allottees include JM Financial Credit Solutions (25 lakh shares) and Ashish Dhawan (17 lakh shares).
Total paid-up equity share capital increased to Rs 341,23,37,420 comprising 34,12,33,742 shares.
The new shares will rank pari passu with existing equity shares, subject to SEBI lock-in regulations.
👀 What to Watch
Investors should note the capital infusion and the participation of marquee investors as a sign of long-term confidence. While there is a slight equity dilution, the strengthened capital base is beneficial for the company's growth prospects.
Religare Enterprises FY26 Income Hits ₹8,493 Cr; Announces Demerger for Health Insurance Focus
Religare Enterprises reported a consolidated total income of ₹8,493 crores for FY26, driven by its health insurance subsidiary, Care Health, which crossed the ₹10,000 crore GWP milestone. The company has approved a demerger to separate its lending and broking businesses into Religare Finvest (RFL), leaving REL as a pure-play health insurance holding company. The Burman Group has increased its stake to 30.3% and committed ₹750 crores in capital. While the insurance segment remains robust with a 24% growth in GWP, the housing finance segment reported a loss of ₹18.6 crores for the year.
Key Highlights
Consolidated total income for FY26 reached ₹8,493 crores with a reported PAT of ₹73.16 crores.
Care Health Insurance GWP grew 24% to ₹11,417 crores, with retail health growing at 34%.
Approved demerger will provide shareholders 1 share of RFL for every 1 share of REL held to unlock value.
Religare Finvest (RFL) reported a profit of ₹89 crores in Q4 FY26 with ₹591 crores in cash reserves.
Promoter (Burman Group) stake increased to 30.3% following a ₹750 crore capital commitment.
👀 What to Watch
Investors should consider the demerger as a significant value-unlocking event for the high-growth health insurance business. Monitor the progress of regulatory approvals for the demerger and the stabilization of the housing finance subsidiary.
Religare FY26 Revenue Hits ₹8,494 Cr; Care Health GWP Grows 24% to ₹11,417 Cr
Religare Enterprises Limited (REL) reported a consolidated revenue of ₹8,494 crore for FY26, primarily driven by its health insurance subsidiary, Care Health, which saw a 24% YoY growth in Gross Written Premium (GWP) to ₹11,417 crore. The NBFC arm, Religare Finvest (RFL), turned profitable with a PAT of ₹138.8 crore for the full year, significantly improving its CRAR to 261.9% and reducing NNPA to 0.8%. The company is also progressing with a strategic demerger to separate its insurance and financial services businesses and has announced a ₹1,500 crore capital raise via convertible warrants.
Key Highlights
Consolidated FY26 revenue reached ₹8,494 Cr, led by Care Health Insurance's GWP of ₹11,417 Cr.
Religare Finvest (RFL) reported a PAT of ₹138.8 Cr in FY26 compared to ₹24 Cr in FY25, with NNPA at a low 0.8%.
Care Health Insurance maintained a 22% market share in the SAHI segment with a claim settlement ratio exceeding 97%.
The Burman Group was designated as Promoters in Feb 2025, currently holding a ~30.3% stake.
Board approved a demerger of the Financial Services business to Religare Finvest Limited for sharper segment focus.
👀 What to Watch
Investors should view the turnaround in the NBFC business and the sustained growth in the health insurance segment as positive indicators. Monitor the upcoming demerger process and the utilization of the ₹1,500 crore capital raise for future expansion.
Religare FY26 Revenue Grows 14.7% to ₹8,494 Cr; Health Insurance GWP Up 24%
Religare Enterprises reported a 14.7% YoY growth in consolidated revenue to ₹8,493.84 crore for FY26, driven largely by the health insurance segment. However, consolidated PAT saw a significant decline to ₹73.16 crore from ₹182.75 crore in FY25. The health insurance business (Care Health) remains the primary growth engine, with Gross Written Premium reaching ₹11,417 crore and a 19.7% market share in the SAHI category. Strategic highlights include a ₹1,500 crore capital raise from the Burman family and the removal of RBI's Corrective Action Plan for the NBFC arm, Religare Finvest.
Key Highlights
Consolidated Revenue increased 14.7% YoY to ₹8,493.84 crore in FY26.
Health Insurance GWP grew 24% to ₹11,417 crore with profitability improving 38% to ₹539 crore.
Religare Finvest (RFL) is now debt-free with a net worth of ₹898.8 crore following RBI CAP removal.
Raised ₹1,500 crore via preferential allotment of convertible warrants to the Burman family and others.
Consolidated PAT for FY26 stood at ₹73.16 crore, down from ₹182.75 crore in the previous fiscal year.
👀 What to Watch
Investors should monitor the scaling of the NBFC business now that regulatory restrictions are lifted and track the progress of the planned demerger. While revenue growth is healthy, the decline in consolidated PAT suggests higher operational or transition costs that need to be evaluated in upcoming quarters.
Religare Enterprises Reports FY26 Standalone Net Loss of ₹33.80 Crore; Revenue Drops 60.7%
Religare Enterprises Limited reported a standalone net loss of ₹33.80 crore for the fiscal year ended March 31, 2026, a slight improvement from the ₹37.54 crore loss in the previous year. However, total income witnessed a significant decline of 60.7%, falling to ₹16.44 crore from ₹41.82 crore in FY25. While the company managed to reduce total expenses by 39.3% to ₹50.36 crore, it remains in a loss-making position. Investors should also note the auditor's emphasis on ongoing income tax litigations and related tax demands.
Key Highlights
Annual standalone total income fell sharply to ₹16.44 crore in FY26 from ₹41.82 crore in FY25.
Net loss for the full year narrowed slightly to ₹33.80 crore compared to ₹37.54 crore in the previous fiscal.
Q4 FY26 standalone net loss stood at ₹12.36 crore versus a loss of ₹17.74 crore in Q4 FY25.
Total annual expenses were reduced to ₹50.36 crore from ₹82.94 crore in the prior year.
Statutory auditors issued an unmodified opinion but included an 'Emphasis of Matter' regarding ongoing income tax litigations.
👀 What to Watch
The company's standalone performance remains weak with a significant drop in revenue and persistent losses. Investors should exercise caution and closely monitor the resolution of tax litigations and the performance of its key subsidiaries in the consolidated report.
Religare Subsidiary RHDFCL Appoints Pankaj Rathi as Executive Director and CFO
Religare Enterprises' step-down subsidiary, Religare Housing Development Finance Corporation Limited (RHDFCL), has appointed Mr. Pankaj Rathi as Executive Director and CFO effective April 06, 2026. Mr. Rathi brings over 15 years of experience in the BFSI sector, specifically in financial reporting, fundraising, and M&A. He previously served as CFO at Grihum Housing Finance, where he successfully raised over $1.3 billion in capital. This appointment is expected to strengthen the strategic and financial leadership of Religare's housing finance business.
Key Highlights
Mr. Pankaj Rathi appointed as Additional Director and Whole-Time Director (ED & CFO) of RHDFCL.
Appointee has over 15 years of experience and previously raised $1.3 billion in capital over 5 years.
Track record includes orchestrating a credit rating migration from AA- to AAA in a previous role.
Appointment is subject to the approval of shareholders of the subsidiary company.
👀 What to Watch
Investors should monitor if this leadership change leads to improved credit ratings and lower borrowing costs for the housing finance subsidiary. The appointee's strong track record in fundraising and M&A is a positive sign for the company's growth trajectory.
Religare Finvest Appoints Srinivasan Karthik as CEO and Managing Director
Religare Enterprises Limited's material subsidiary, Religare Finvest Limited (RFL), has appointed Mr. Srinivasan Karthik as its Chief Executive Officer and Key Managerial Personnel effective May 05, 2026. Mr. Karthik brings over 30 years of extensive experience, including a 10-year tenure at HDB Financial Services where he scaled consumer and asset finance portfolios. His further designation as Managing Director is currently pending approval from the Reserve Bank of India (RBI) and shareholders. This appointment is a strategic move to strengthen the leadership at RFL, leveraging his expertise in digital transformation and financial services.
Key Highlights
Mr. Srinivasan Karthik appointed as CEO of Religare Finvest Limited effective May 05, 2026
Brings 30+ years of experience in financial services, consumer financing, and asset financing
Previously spent a decade at HDB Financial Services building large-scale loan portfolios
Educational credentials include a B.Tech from IIT Delhi and a PGDM from IIM Bangalore
Designation as Managing Director is subject to upcoming RBI and shareholder approvals
👀 What to Watch
Investors should monitor the regulatory approval process for the Managing Director role as it signals stability in the subsidiary's leadership. The appointment of a high-pedigree professional from a major NBFC like HDB Financial is a positive indicator for RFL's future growth and digital strategy.
Religare Subsidiary Care Health's Tax Liability Reduced to ₹45.16 Cr via Rectification Order
Religare Enterprises' material subsidiary, Care Health Insurance Limited (CHIL), has received a rectification order from the Income Tax department for Assessment Year 2023-24. The order corrects a technical error in the initial demand, effectively reducing the net tax liability from ₹89.02 Crore to ₹45.16 Crore. While this reduction is a positive development, CHIL continues to contest the remaining additions through an appeal filed with the appropriate authorities. The financial impact of this subsidiary is consolidated into Religare's overall performance.
Key Highlights
Rectification order received under Section 154 of the Income-tax Act for AY 2023-24
Net tax liability reduced by approximately 49%, from ₹89.02 Crore to ₹45.16 Crore
The correction was issued to fix a technical error in the initial tax computation
CHIL has already filed an appeal against the original additions, which remains pending for adjudication
👀 What to Watch
Investors should view this as a positive development that reduces immediate financial pressure on the subsidiary. Monitor the outcome of the pending appeal for further potential reductions in tax liability.
Religare Appoints Arjun Lamba as Executive Director for 5-Year Term
Religare Enterprises has received shareholder approval to appoint Mr. Arjun Lamba as a Whole Time Director (Executive Director) for a five-year term effective from April 01, 2026. Mr. Lamba, who has over 23 years of experience in Indian capital markets, was previously a Non-Executive Director and played a pivotal role in the Burman Family's acquisition of the company. This transition to an executive role signifies a more hands-on leadership approach by the major stakeholders. The appointment was confirmed following the voting results of the Extra Ordinary General Meeting held on May 05, 2026.
Key Highlights
Appointment of Mr. Arjun Lamba as Whole Time Director for a 5-year term starting April 01, 2026
Mr. Lamba brings over 23 years of experience in capital markets and is the founder of Guardian Advisors
Played a critical role in the Burman Family's acquisition of both Religare Enterprises and Eveready Industries
Holds board positions across key subsidiaries including Care Health Insurance and Religare Finvest
The appointment was approved by shareholders in the EGM held on May 05, 2026
👀 What to Watch
Investors should view this as a positive step towards leadership stability and a sign of the Burman group's commitment to the company's turnaround. Monitor the company's progress in resolving legacy regulatory issues under this strengthened executive leadership.
Religare Shareholders Approve Office Shift and Appointment of Arjun Lamba as Executive Director
Religare Enterprises Limited held an Extraordinary General Meeting (EGM) on May 05, 2026, where shareholders approved two key special resolutions. The first resolution to shift the company's registered office from Delhi to Haryana passed with a 98.48% majority. The second resolution, appointing Mr. Arjun Lamba as a Whole Time Director (Executive Director) and approving his remuneration, was passed with 95.53% support. While overall approval was high, institutional investors showed notable dissent on the director's appointment, with 21.13% of their votes cast against it.
Key Highlights
Resolution to shift registered office from Delhi to Haryana approved with 98.48% votes in favor.
Appointment of Mr. Arjun Lamba as Whole Time Director approved with 95.53% of total votes polled.
Institutional investors cast 21.13% of their votes against the appointment and remuneration of Mr. Lamba.
Total voter turnout for the EGM stood at 56.7% of the total outstanding shares.
A total of 18,87,47,494 votes were polled across 77,860 shareholders on record.
👀 What to Watch
Investors should note the successful management transition but remain aware of the significant institutional dissent (21%) regarding the new Executive Director's appointment. The office relocation is a routine administrative change and is unlikely to impact the stock's fundamental value.
Religare EGM: Shifting Registered Office to Haryana and Appointing New Executive Director
Religare Enterprises Limited held an Extraordinary General Meeting (EGM) on May 05, 2026, to vote on two key special resolutions. The first resolution involves shifting the company's registered office from Delhi to Haryana, necessitating an amendment to the Memorandum of Association. The second resolution seeks approval for the appointment of Mr. Arjun Lamba as a Whole Time Director (Executive Director) along with his remuneration terms. Final voting results are expected to be released within two working days of the meeting's conclusion.
Key Highlights
EGM conducted on May 05, 2026, via video conferencing to pass two Special Resolutions.
Proposed shifting of the Registered Office from the National Capital Territory of Delhi to the State of Haryana.
Appointment of Mr. Arjun Lamba (DIN: 00124804) as Whole Time Director (Executive Director).
Voting results and Scrutinizer Report to be submitted within 48 hours of the meeting.
👀 What to Watch
Investors should monitor the official voting results to confirm shareholder approval for the new executive leadership and the relocation. These changes are largely administrative but reflect the company's evolving management structure.
Religare Subsidiary Care Health Tax Demand Reduced to ₹86.66 Cr from ₹173.32 Cr
Religare Enterprises' material subsidiary, Care Health Insurance Limited (CHIL), has received a rectification order from the Income Tax Department for Assessment Year 2022-23. The order corrects a technical computation error, effectively reducing the net tax liability by 50% from ₹173.32 Crores to ₹86.66 Crores. While this reduction is a positive development for the company's balance sheet, an appeal against the underlying additions in the assessment order remains pending. The financial impact of this subsidiary will be reflected in Religare's consolidated financial statements.
Key Highlights
Tax liability for subsidiary Care Health Insurance reduced from ₹173.32 Crores to ₹86.66 Crores.
Rectification order issued under Section 154 of the Income-tax Act, 1961 for AY 2022-23.
The reduction follows the correction of a technical error in the original tax computation.
An appeal against the remaining additions is currently pending with the appropriate authorities.
👀 What to Watch
Investors should view this as a positive development that significantly reduces a potential cash outflow. Monitor the outcome of the pending appeal which could further reduce the remaining tax liability.
Religare Subsidiary Care Health Appoints Ajay Kumar Shah as MD & CEO for 5-Year Term
Religare Enterprises has announced the appointment of Ajay Kumar Shah as the Managing Director & CEO of its material subsidiary, Care Health Insurance Limited (CHIL), effective April 26, 2026. Mr. Shah, who has been with CHIL for 14 years, succeeds the outgoing leadership as part of an internal succession plan. The appointment has already received necessary approval from the IRDAI for a five-year tenure. Given his history as Chief Business Officer where he oversaw a 30x growth in Gross Written Premium, the transition is expected to be stable.
Key Highlights
Ajay Kumar Shah appointed as MD & CEO of Care Health Insurance for a 5-year term starting April 26, 2026
IRDAI has already granted approval for the appointment, ensuring regulatory compliance
Mr. Shah has over 30 years of experience and has spent 14 years at CHIL in various leadership roles
Under his leadership as Chief Business Officer, CHIL's Gross Written Premium (GWP) grew more than 30-fold over 10 years
The appointment follows an internal succession plan, suggesting continuity in business strategy
👀 What to Watch
Investors should take confidence in the internal succession and the appointee's strong track record of scaling the insurance business. No immediate action is required, but monitor the subsidiary's growth trajectory under the new leadership.
Religare Subsidiary Care Health Appoints Ajay Kumar Shah as MD & CEO for 5 Years
Religare Enterprises has announced the appointment of Mr. Ajay Kumar Shah as the Managing Director & CEO of its material subsidiary, Care Health Insurance Limited (CHIL), for a five-year term starting April 26, 2026. Mr. Shah, a Chartered Accountant with over 30 years of experience, has been with CHIL for 14 years and currently serves as its Chief Business Officer. The appointment has already received approval from the IRDAI and follows an internal succession plan. Under his business leadership over the last decade, CHIL's Gross Written Premium (GWP) has grown more than 30 times.
Key Highlights
Mr. Ajay Kumar Shah appointed as MD & CEO of Care Health Insurance for a 5-year term effective April 26, 2026.
IRDAI approval has been secured for the appointment, with shareholder approval pending.
Mr. Shah has 14 years of experience at CHIL and over 30 years in the insurance and financial services sectors.
CHIL's Gross Written Premium (GWP) grew over 30x during his tenure leading business verticals.
The appointment is part of an internal succession plan aimed at maintaining growth and operational stability.
👀 What to Watch
Investors should view this as a positive move for leadership continuity in Religare's most significant subsidiary. The appointment of an internal high-performer suggests a stable growth trajectory for Care Health Insurance.
Religare Appoints Ajay Kumar Shah as MD & CEO of Care Health Insurance for 5-Year Term
Religare Enterprises has announced the appointment of Mr. Ajay Kumar Shah as the Managing Director and CEO of its material subsidiary, Care Health Insurance Limited (CHIL), effective April 26, 2026. Mr. Shah, who has been with CHIL for 14 years, previously served as the Chief Business Officer and has over 30 years of experience in the financial services sector. Under his leadership of business verticals over the last decade, CHIL's Gross Written Premium (GWP) has grown more than 30-fold. The appointment has already received approval from the IRDAI, ensuring a smooth leadership transition for this critical business unit.
Key Highlights
Mr. Ajay Kumar Shah appointed as MD & CEO of Care Health Insurance for a 5-year term starting April 26, 2026.
CHIL's Gross Written Premium (GWP) grew over 30x during his 10-year tenure leading business verticals.
The appointment has received formal approval from the IRDAI and follows an internal succession plan.
Mr. Shah is a Chartered Accountant with over 30 years of experience in Insurance and Financial Services.
👀 What to Watch
Investors should view this as a positive development for business continuity and growth, given the appointee's significant role in CHIL's historical scaling. Monitor the subsidiary's performance as it remains a primary value driver for Religare Enterprises.
Religare to Hold EGM for Office Shift and Appointment of Executive Director with ₹9 Cr Salary
Religare Enterprises has scheduled an Extraordinary General Meeting (EGM) on May 05, 2026, to seek shareholder approval for shifting its registered office from Delhi to Haryana. A key agenda item is the appointment of Mr. Arjun Lamba as Whole Time Director for a five-year term starting April 01, 2026. The proposed remuneration for Mr. Lamba includes a fixed salary of ₹9.00 crore per annum, with potential annual hikes of up to 25%. Additionally, he will be eligible for a variable bonus of up to 50% of his fixed pay and participation in the company's ESOP plan.
Key Highlights
Extraordinary General Meeting (EGM) scheduled for May 05, 2026, via Video Conferencing.
Proposal to shift the Registered Office from the National Capital Territory of Delhi to the State of Haryana.
Appointment of Mr. Arjun Lamba as Whole Time Director (Executive Director) for a 5-year tenure until March 2031.
Proposed fixed remuneration for the new Executive Director set at ₹9.00 crore per annum.
Variable pay component capped at 50% of fixed pay, alongside eligibility for Employee Stock Option Plans (ESOPs).
👀 What to Watch
Investors should review the proposed executive remuneration package and the rationale for the office relocation during the EGM. Monitor the voting outcomes to gauge shareholder sentiment regarding the high-value management compensation.
Religare Subsidiary Care Health Gets Stay from Bombay HC on ₹35.36 Cr GST Demand & Penalty
Religare Enterprises' material subsidiary, Care Health Insurance Limited (CHIL), has obtained a stay order from the Bombay High Court against a GST demand order. The original demand included ₹17.68 crore in GST and an equivalent penalty of ₹17.68 crore, totaling approximately ₹35.36 crore excluding interest. The dispute pertains to SEZ-related matters for the period FY 2017-18 to FY 2023-24. The stay provides temporary financial relief as the company contests what it describes as an industry-wide tax issue.
Key Highlights
Bombay High Court granted a stay on the GST order-in-original until final disposal of the writ petition.
The total financial implication involves a tax demand of ₹17.68 crore and a penalty of ₹17.68 crore.
The tax dispute covers a seven-year period from July 2017 to March 2024 regarding SEZ matters.
Religare identifies the tax demand as part of an industry-wide issue rather than a company-specific lapse.
👀 What to Watch
Investors should monitor the final outcome of the writ petition as the stay is temporary, though it prevents immediate cash outflow. The resolution of this 'industry-wide' issue will be a significant indicator for the subsidiary's long-term tax liabilities.
Religare Appoints Arjun Lamba as Executive Director for 5 Years; New Chairperson Named
Religare Enterprises has announced a significant leadership transition, appointing Mr. Arjun Lamba as Whole Time Director (Executive Director) for a five-year term effective April 1, 2026. Mr. Lamba, who has over 23 years of experience in capital markets, was notably involved in the Burman family's acquisition efforts for Religare and Eveready. Additionally, Mr. Rajender Mohan Malla will serve as the Non-Executive Chairperson for a short interim period from April 1 to June 30, 2026. These appointments are subject to shareholder approval and signal a potential shift in strategic direction under the influence of major stakeholders.
Key Highlights
Mr. Arjun Lamba appointed as Whole Time Director for a 5-year term starting April 1, 2026
Mr. Rajender Mohan Malla appointed as Non-Executive Chairperson for a 3-month tenure ending June 30, 2026
Mr. Lamba brings 23+ years of experience and is the founder of Guardian Advisors, a SEBI-registered PMS
Appointment is significant as Mr. Lamba played a key role in the Burman family's acquisition of Religare Enterprises
The leadership changes are subject to the approval of the company's shareholders
👀 What to Watch
Investors should monitor how this leadership change affects the ongoing corporate governance dynamics and the potential takeover bid by the Burman family. The short-term appointment of the Chairperson suggests further board restructuring may be expected by mid-2026.
Religare Subsidiary Care Health Insurance Receives Rs 140.20 Cr Income Tax Demand
Religare Enterprises' material subsidiary, Care Health Insurance Limited (CHIL), has received income tax demand orders totaling Rs 140.20 crore for the assessment years 2023-24 and 2024-25. The demand arises from disallowances related to claim provisions (IBNR/IBNER) and marketing expenses, which the company claims are industry-wide issues. CHIL expects to reduce the demand to approximately Rs 96 crore through a rectification application and intends to appeal the orders. The company notes that similar issues have been adjudicated in its favor by judicial forums in previous years.
Key Highlights
Cumulative income tax demand of Rs 140.20 crore (including interest) issued against Care Health Insurance Limited.
Demand pertains to Assessment Years 2023-24 and 2024-25 regarding disallowances of claim provisions and marketing expenses.
Company estimates the demand will be rectified down to approximately Rs 96 crore post-correction of computation errors.
CHIL plans to file an appeal, citing that IBNR/IBNER issues were previously settled in their favor by the Delhi High Court.
The tax demand, if finalized, will impact the consolidated financials of Religare Enterprises Limited.
👀 What to Watch
Investors should monitor the outcome of the rectification and appeal process as the demand represents a significant contingent liability. While the company has a history of favorable rulings on these specific issues, the immediate demand may create short-term pressure on the stock.
Religare Subsidiary Care Health Insurance Receives IRDAI Show Cause Notice
Religare Enterprises Limited's material subsidiary, Care Health Insurance Limited (CHIL), has received a Show Cause Notice (SCN) from IRDAI dated March 02, 2026. The notice follows a thematic onsite inspection conducted in February 2025 and alleges violations of multiple regulatory frameworks, including policyholder interest and actuarial functions. While the company currently reports no material financial impact, any future penalties will be consolidated into Religare's financial statements. CHIL is in the process of filing a response and taking remedial actions as advised by the regulator.
Key Highlights
IRDAI issued a Show Cause Notice to material subsidiary Care Health Insurance on March 02, 2026.
The notice is based on a thematic onsite inspection conducted from February 10 to February 14, 2025.
Alleged violations involve Master Circulars on Operations, Policyholder Interests, and Health Insurance Business (2024).
Management states there is no immediate material impact on financials or operations of the listed entity.
CHIL is preparing a formal reply and implementing remedial steps to address IRDAI observations.
👀 What to Watch
Investors should monitor the final adjudication of this notice as any significant penalty or operational restriction on the insurance subsidiary could affect Religare's consolidated valuation. Maintain a watch on the regulatory compliance status of Care Health Insurance.
